Clinical Trials Logo
  1. Home
  2. Pulmonary Valve Insufficiency
  3. NCT05809856

Feasibility Study to Evaluate the Safety of the Autologous GrOwnValve Transcatheter Pulmonary Heart Valve — GECT  

Pulmonary Valve Insufficiency Clinical Trial

Official title:
A First-in-Human Feasibility Study to Evaluate the Safety (and Short Term Effectiveness) of the Autologous GrOwnValve Transcatheter Pulmonary Heart Valve [GECT]

Clinical Trial Summary

Aim of this study is to investigate the clinical safety of a novel pediatric heart valve.

Clinical Trial Description

Defective or diseased pulmonary heart valves do not recover. If left untreated, pediatric and adult patients alike, face serious risks of progressive heart failure and death. Due to the insufficient care of children with heart valve defects, the valve replacement with regenerative, remodeling, and growth potential remains an unmet medical need. Therefore, the first pediatric heart valve (GrOwnValve) was developed to overcome the current limitations, which should offer regenerative potential that adapts to the somatic growth of the child. The study aims to investigate the safety and provide the first initial efficacy estimates of the transcatheter implantable GrOwnValve. This first prospective, non-randomized, single center trial in 7 study subjects (≥ 18 years of age) should be conducted to assess the devices safety for clinical application. The novel interdisciplinary solution approach is based on the combination of individualized 3D modeling, viable autologous tissue (contrary to all other prosthetic heart valves on the market), and preservation of the regenerative capacity of the valve replacement by maintaining the vitality of heart valve cells and tissue through the application of a novel crosslinker in the tissue preparation process. The GrOwnValve prothesis has the potential to be the first durable and regenerative heart valve for adults. Fabrication is performed on-demand in the operating room. The trial should be the first clinical investigation assessing this novel heart valve replacement approach. We are aiming for the GrOwnValve to be the standard of care, replacing current solutions. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05809856
Study type Interventional
Source Charite University, Berlin, Germany
Contact Boris Schmitt, Dr.
Phone +49 30 4593 2846
Email boris.schmitt@charite.de
Status Recruiting
Phase N/A
Start date December 18, 2023
Completion date December 31, 2029
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05378386 - ALTERRA Post-Approval Study
Active, not recruiting NCT03441971 - Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction N/A
Recruiting NCT02744677 - COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction N/A
Active, not recruiting NCT02987387 - COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction
Completed NCT01092442 - CryoValve SG Pulmonary Human Heart Valve Post Clearance Study N/A
Completed NCT05090228 - Right Ventricle Remodeling After Pulmonary Valve Replacement and Percutaneous Pulmonary Valve Insertion
Completed NCT02656290 - COMMENCE Pulmonary: Clinical Evaluation of Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement N/A
Completed NCT00259207 - Pulmonary Valve Replacement in Large Right Ventricular Outflow Tract Phase 3
Completed NCT02555319 - A Feasibility Study to Evaluate the Safety and Short-term Effectiveness of Transcatheter Pulmonary Valve (TPV) N/A
Completed NCT00676689 - COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV N/A
Completed NCT00112320 - Comparison of Two Pulmonary Valve Replacement Methods to Treat Tetralogy of Fallot N/A
Recruiting NCT04860765 - COMPASSION S3 Post-Approval Study